Zhejiang Jingxin Pharmaceutical Co., Ltd.

Total Valuation

Zhejiang Jingxin Pharmaceutical Co., Ltd. carries a market capitalization of 12.86B, placing it among publicly traded companies globally. Its enterprise value stands at 10.46B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Zhejiang Jingxin Pharmaceutical Co., Ltd. currently has 861.03M shares outstanding.

Valuation Ratios

Zhejiang Jingxin Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 15.27. The price-to-sales ratio is 2.65, and the price-to-book ratio stands at 2.76.

Enterprise Valuation

On an enterprise value basis, Zhejiang Jingxin Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 12.99 and an EV/FCF ratio of 43.76. The EV/Sales ratio of 2.60 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.99 provides insight into valuation relative to core operating earnings.

Financial Position

Zhejiang Jingxin Pharmaceutical Co., Ltd. maintains a current ratio of 1.36, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 5.79, indicating elevated leverage, while an interest coverage ratio of 159.16 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Zhejiang Jingxin Pharmaceutical Co., Ltd. posts a return on equity of 18.84 and a return on invested capital of 11.53.

Taxes

Over the trailing twelve months, Zhejiang Jingxin Pharmaceutical Co., Ltd. has paid 108.66M in income taxes, reflecting an effective tax rate of 13.35.

Stock Price Statistics

Zhejiang Jingxin Pharmaceutical Co., Ltd.'s stock has gained approximately 0.47106326% over the past 52 weeks. The 50-day moving average sits at 13.59, while the 200-day moving average is 16.88.

Income Statement

Over the trailing twelve months, Zhejiang Jingxin Pharmaceutical Co., Ltd. generated 4.03B in revenue and converted that into 697.72M in net income, yielding earnings per share of 0.86. EBITDA reached 804.89M, while operating income came in at 804.89M.

Balance Sheet

Zhejiang Jingxin Pharmaceutical Co., Ltd. holds 547.32M in cash and equivalents against 317.99M in total debt, resulting in a net debt position of -139.69M. Total book value stands at 3.86B, with working capital of 749.99M providing operational flexibility.

Cash Flow

After subtracting -234.61M in capital expenditures, free cash flow totaled -234.61M - equivalent to -0.29 per share.

Margins

Zhejiang Jingxin Pharmaceutical Co., Ltd. operates with a gross margin of 48.92, reflecting its pricing power and cost economics. The operating margin of 20.00 and net profit margin of 17.33 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Zhejiang Jingxin Pharmaceutical Co., Ltd.'s most recent stock split took place on May 28, 2021 with a 5:6 split ratio.

Scores

Zhejiang Jingxin Pharmaceutical Co., Ltd. posts an Altman Z-Score of 4.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.